

3. On page 62800 at the top of the second column, at the end of the first paragraph, the following two sentences are added:

Likewise, FDA has determined under § 314.161 that those ANDAs that used Oxandrin (oxandrolone) tablets, 2.5 mg and 10 mg, approved in NDA 013718 as their reference listed drug were withdrawn for reasons of safety or effectiveness. Accordingly, the Agency will remove Par Pharmaceutical Inc.'s ANDA 077827 for oxandrolone tablets, 2.5 mg and 10 mg; Roxane Laboratories, Inc.'s ANDA 077249 for oxandrolone tablets, 2.5 mg and 10 mg; Sandoz Inc.'s ANDA 076897 for oxandrolone tablets, 2.5 mg and 10 mg; and Upsher Smith Laboratories LLC's ANDA 076761 for oxandrolone tablet, 2.5 mg, and ANDA 078033 for oxandrolone tablet, 10 mg, from the list of drug products published in the Orange Book per § 314.162.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–20503 Filed 10–6–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Clinical Center; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors of the NIH Clinical Center.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual grant applications conducted by the Clinical Center, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors of the NIH Clinical Center.

Date: October 26–27, 2026.

Time: 9:30 a.m. to 1:00 p.m.

Agenda: The Review and Discussion of the Department of Perioperative Medicine, Department of Transfusion Medicine, and Rehabilitation Medicine Department.

Address: National Institutes of Health Clinical Center, Building 10, 10 Center Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Leighton Chan, Ph.D., Chief Scientific Officer/Scientific Director, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, (301) 496–4733, chanle@cc.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Dated: October 5, 2026.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–20557 Filed 10–6–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Digestive, Kidney and Urological Systems Integrated Review Group; Pathobiology of Kidney Disease Study Section.

Date: November 4–5, 2026.

Time: 9:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Jason D. Hoffert, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–496–9010, hoffertj@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Pulmonary and Vascular Pathobiology, Hemostasis and Thrombosis.

Date: November 4, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Vladimir Bogdanov, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Room 801G, Bethesda, MD 20892, 301–594–6602, bogdanovv2@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Social, Biobehavioral, and Population Health: NIH Collaborative International Research Projects (PF5)—Panel A.

Date: November 4–5, 2026.

Time: 9:00 a.m. to 5:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Shareen Iqbal, Ph.D., MPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–594–0683, iqbalsha@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Basic Neurosciences.

Date: November 4–5, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Baila Sara Hall, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–435–1722, baila.hall@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Training and Career Development: Clinical Care, Treatment & Disease Management.

Date: November 4–5, 2026.

Time: 9:00 a.m. to 9:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Trina Colleen Salm Ward, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–594–5254, salmwardtc@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Training: Biomedical Sciences.

Date: November 4–5, 2026.

Time: 9:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Sonia Ivette Ortiz-Miranda, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–496–3859, sonia.ortiz-miranda@nih.gov.